

Treatment-Experienced Patients All Patients

TABLE 137: SVR GENOTYPE 4 TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	SOF12 + RBV12	1.41 (0.85 to 2.04)	25.45 (–10.27 to 47.65)
DCV24 + ASU24 + PR24		1.55 (1.18 to 2.18)	33.59 (13.37 to 51.91)
DCV24 + ASU24 + PR24	SOF24 + RBV24	1.09 (0.87 to 1.77)	7.45 (–12.29 to 41.70)
Random effect model	Residual deviance	3.976 vs. 4 data points	
	Deviance information criteria	19.486	
Fixed effect model	Residual deviance	3.899 vs. 4 data points	
	Deviance information criteria	19.339	

ASU = asunaprevir; CrI = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.